Clinical Trials

17 enrolled

Leukemia, Myeloid, Acute

NCT07529535 2026-04-17

A First-in-Human Study of ALK-N001 for Injection in Patients With Advanced Solid Tumors

Phase 1 Suspended

16 enrolled

Advance Solid Tumors

NCT06484777 2026-04-16

A Clinical Study of SHR-9539 in Patients With Multiple Myeloma

138 enrolled

Plasma cell

Multiple Myeloma

NCT03132454 2026-04-15

Palbociclib and Sorafenib, Decitabine, or Dexamethasone in Treating Patients With Recurrent or Refractory Leukemia

LymphoidOther hematologic neoplasm

32 enrolled

Leukemia, Myeloid, Acute, Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT03896269 2026-04-14

CPX-351 in Treating Patients With Relapsed or Refractory High Risk Myelodysplastic Syndrome or Chronic Myelomonocytic Leukemia

38 enrolled

Leukemia, Myelomonocytic, Chronic

NCT01861314 2026-04-13

Bortezomib, Sorafenib Tosylate, and Decitabine in Treating Patients With Acute Myeloid Leukemia

15 enrolled

Leukemia, Myeloid, Acute

NCT03041688 2026-04-13

Testing a New Chemotherapy Drug, KRT-232 (AMG-232) in Combination With Decitabine and Venetoclax in Patients With Acute Myeloid Leukemia

58 enrolled

Leukemia, Myeloid, Acute

NCT05879627 2026-04-13

To Evaluate the Safety, Tolerance and Pharmacokinetics of BAT8007 for Injection in Patients With Advanced Solid Tumors

Phase 1 Terminated

93 enrolled

Phase 1 Not yet recruiting

Advanced Solid Tumors

NCT07012044 2026-04-13

A Study to Find the Highest Dose of Cedazuridine and Decitabine Combination With Filgrastim as a Treatment Option After Hematopoietic Stem Cell Transplant in Children With High-Risk Acute Myeloid Leukemia

47 enrolled

Leukemia, Myeloid, Acute

NCT03017131 2026-04-06

Genetically Modified T Cells and Decitabine in Treating Patients With Recurrent or Refractory Ovarian, Primary Peritoneal, or Fallopian Tube Cancer

9 enrolled

Gynecologic

Fallopian Tube Neoplasms, Ovarian Neoplasms

NCT05848466 2026-03-30

Assessment of Safety, Tolerability and Pharmacokinetics With BAT8010 for Injection in Advanced Malignant Solid Tumors Patients

23 enrolled

Advanced or Metastatic Solid Tumors

NCT06482905 2026-03-24

Safety and Efficacy Study of TX103 CAR-T Cell Therapy for Recurrent or Progressive Grade 4 Glioma.

52 enrolled

CNS

Glioma

NCT05627232 2026-03-12

Tazemetostat and Palbociclib With CPX-351for R/R AML

24 enrolled

Leukemia, Myeloid, Acute

NCT03969446 2026-03-05

Pembrolizumab and Decitabine With or Without Venetoclax in Treating Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome That Is Newly-Diagnosed, Recurrent, or Refractory

MyeloidOther hematologic neoplasm

54 enrolled

Myelodysplastic Syndromes, Leukemia, Myeloid, Acute

NCT03358719 2026-02-27

DEC-205/NY-ESO-1 Fusion Protein CDX-1401, Poly ICLC, Decitabine, and Nivolumab in Treating Patients With Myelodysplastic Syndrome or Acute Myeloid Leukemia

Classical hematologyMyeloidOther hematologic neoplasm

8 enrolled 9 charts

Anemia, Refractory, Myelodysplastic Syndromes, Leukemia, Myeloid, Acute, Leukemia, Myelomonocytic, Chronic

NCT07434609 2026-02-25

Evaluation of T320, an Anti-Tissue Factor Antibody-Drug Conjugate, in Patients With Advanced Solid Tumors

Phase 1 Not yet recruiting

150 enrolled

Advanced Solid Tumor (Phase 1)

NCT04915612 2026-02-20

Liposomal Cytarabine, Daunorubicin, and Gemtuzumab Ozogamicin for the Treatment of Relapsed Refractory Pediatric Patients With Acute Myeloid Leukemia

1 enrolled

Leukemia, Myeloid, Acute

NCT03995888 2026-02-12

Assessing Radio-hybrid Prostate Specific Membrane Antigen (rhPSMA-7.3) (18F) in Healthy Volunteers and Subjects With Prostate Cancer

24 enrolled 10 charts

Genitourinary

Prostatic Neoplasms

NCT05620017 2026-02-09

Evaluate the Safety, Tolerability and Pharmacokinetic Characteristics of BAT8008 for Injection

182 enrolled

Advanced Solid Tumors

NCT04081688 2026-02-05

Atezolizumab and Varlilumab in Combination With Radiation Therapy for NSCLC

Phase 1 Terminated

16 enrolled 9 charts

Thoracic

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT06565689 2026-02-05

A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of YK012

48 enrolled

Lymphoid

Recurrence, Lymphoma, B-Cell

NCT06574568 2026-02-05

A Study of YKST02 in Participants With Relapsed or Refractory Multiple Myeloma

70 enrolled

Plasma cell

Multiple Myeloma, Recurrence

NCT06792552 2026-01-29

A Phase I Study of SIM0505 in Participants With Advanced Solid Tumors

414 enrolled

Advanced Solid Tumors

NCT07369505 2026-01-27

Sapu003 in Advanced mTOR-sensitive Solid Tumors

EndocrineGastrointestinalGenitourinaryNET

27 enrolled

Carcinoma, Renal Cell, Carcinoma, Hepatocellular, Tuberous Sclerosis, Neuroendocrine Tumors

NCT06997094 2026-01-26

Decitabine in Combination With Standard of Care Therapy for the Treatment of Surgically Resectable HPV-Negative Head and Neck Cancer

24 enrolled

Head & Neck

Human Papillomavirus-Negative Neck Squamous Cell Carcinoma

NCT07368478 2026-01-26

A Study to Evaluate the Safety, Tolerability, Pharmacokinetics (PK), and Preliminary Efficacy of BC2027 in Patients With Advanced Solid Malignancies